

Applicants: Gloria C. Li, et al.  
Serial No.: 09/750,410  
Filed : December 28, 2000  
Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (previously presented) A method for increasing the susceptibility of a cell to DNA-damaging agents, comprising introducing into the cell *in vitro* an antisense oligonucleotide that specifically hybridizes to a nucleic acid encoding a human DNA-dependent protein kinase subunit so as to prevent expression of the human DNA-dependent protein kinase subunit; wherein the antisense oligonucleotide is in an amount sufficient to increase the sensitivity of the cell to heat, chemical, or radiation-induced DNA damage; and wherein the human DNA-dependent protein kinase subunit is a human DNA-dependent protein kinase catalytic subunit, a Ku70, or a Ku80.
2. (original) The method of claim 1, wherein the antisense oligonucleotide is enclosed in a liposome prior to introduction into the cell.
- 3-14. (canceled)
15. (currently amended) An antisense oligonucleotide that specifically hybridizes to a nucleic acid encoding a human DNA-dependent protein kinase subunit, wherein the human DNA-dependent protein kinase subunit is a ~~human~~ DNA-

Applicants: Gloria C. Li, et al.  
Serial No.: 09/750,410  
Filed : December 28, 2000  
Page 3

~~dependent protein kinase catalytic subunit, or Ku70, so as to prevent expression of the human DNA-dependent protein kinase subunit.~~

16. (previously presented) The antisense oligonucleotide of claim 15 linked to a ribozyme.
17. (canceled)
18. (previously presented) The antisense oligonucleotide of claim 15 operably linked to a regulatory element.
19. (original) The antisense oligonucleotide of claim 18, wherein the regulatory element is an inducible promoter.
20. (original) The antisense oligonucleotide of claim 18, wherein the regulatory element is a heat shock promoter.
21. (original) An expression vector adapted for the expression of the antisense oligonucleotide of claim 15.
22. (previously presented) An expression vector adapted for the expression of the antisense oligonucleotide of claim 16.
23. (original) A pharmaceutical composition comprising the antisense oligonucleotide of claim 15 and a carrier.
24. (previously presented) A pharmaceutical composition comprising the antisense oligonucleotide of claim 16.
- 25-26. (canceled)